12,372 trials
End Stage Renal Disease · Chronic Kidney Disease
Primary: Incidence of Treatment-emergent Adverse Events — 31.6; 35.1; 95.1 percentage of participants
Diabetic Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Stress Disorders, Posttraumatic
Primary: PTSD Symptoms in Children 6 Weeks Post-injury — 12.6; 13.6 Units on a scale — p=.69
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 50.0; 76.5; 86.7; 90.3 percentage of participants
Polycystic Ovary Syndrome · Hypovitaminosis D
Primary: Ultrasound Examination of Number of Follicles and Ovarian Volume — 7; 0; 5; 11 participants — p=0.001
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. — -12.24; -14.17; -0.95 Score on a scale — p=<0.0001
Idiopathic Gastroparesis
Primary: Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits — 15; 14 participants — p=0.86
Vesicoureteral Reflux · Urinary Tract Infections
Primary: Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up — 39; 72 participants — p=<0.001
Breast Cancer · Neurotoxicity
Primary: The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score. — 12.2; 12.6; 3.9; 2.6 units on a scale*months — p=0.84
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -34.4 percentage of curvature change
Head and Neck Neoplasms · Carcinoma, Squamous Cell
Primary: Progression-free Survival (PFS) Based on Central Independent Review — 2.63; 1.74 months — p=0.0257
Pediatric Glaucoma · Elevated IOP in Pediatric Patients · Ocular Hypertension in Pediatric Patients
Primary: Mean Change From Baseline in IOP at Month 3 — -5.4; -5.3 mmHg
Chronic Sinusitis
Primary: Percentage of Sinuses Requiring Post-operative Intervention — 33.3; 46.9 percentage of sinuses — p=0.0280
Breast Cancer
Primary: Proportion of Participants With No Pain Immediately After Surgery
Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 53.6; 54.7 percentage of participants — p=0.001